Abstract: The present disclosure relates to leveraging explainable machine learning methods and feature importance mechanisms as a mechanism for gene discovery and furthermore leveraging the outputs of the gene discovery to recommend ideal gene expression profiles and the requisite genome edits that are conducive to a desired phenotype. Particularly, aspects of the present disclosure are directed to obtaining gene expression profiles for a set of genes measured in a tissue sample of a plant, inputting the gene expression profiles into a prediction model constructed for a task of predicting a phenotype as output data, generating, using the prediction model, the prediction of the phenotype for the plant, analyzing, by an explainable artificial intelligence system, decisions made by the prediction model to predict the phenotype, and identifying a set of candidate gene targets for the phenotype as having a largest contribution or influence on the prediction based on the analyzing.

Abstract: A device includes arrays of Non-Volatile Memory (NVM) cells. Reference sequences representing portions of a genome are stored in respective groups of NVM cells. Exact matching phase substring sequences representing portions of at least one sample read are loaded into groups of NVM cells. One or more groups of NVM cells are identified where the stored reference sequence matches the loaded exact matching phase substring sequence using the arrays at Content Addressable Memories (CAMs). Approximate matching phase substring sequences are loaded into groups of NVM cells. One or more groups of NVM cells are identified where the stored reference sequence approximately matches the loaded approximate matching phase substring sequence using the arrays as Ternary CAMs (TCAMs). At least one of the reference sequence and the approximate matching phase substring sequence for each group of NVM cells includes at least one wildcard value when the arrays are used as TCAMs.

Abstract: Methods for identifying patients diagnosed with treatment resistant or refractory depression, pain or other clinical indications who are eligible to receive N-methyl-D-aspartate receptor antagonist, glycine receptor beta (GLRB) modulator, or ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-based therapies to include determining the appropriate medication, an optimal dose for each patient, and determining which patients are not eligible to receive the therapy. The pharmacogenomic clinical decision support assays include targeted single nucleotide polymorphisms and clinical values or a combination of targeted single nucleotide polymorphisms, targeted ketamine-specific expansion and contraction of topologically associated domains, and clinical values. The methods described herein allow for a more effective determination of which patients will experience drug efficacy and which patients will experience adverse drug events.

Abstract: The present disclosure relates to the use of next generation technologies and analysis using a k-mer based approach which is depth-informed to classify microorganism and estimate abundance in single or mixed microorganismal populations in a rapid manner. The disclosure relates to methods for identifying taxa from environmentally or patient collected samples and processing these samples in a privacy-preserving manner.

Abstract: The invention relates to a method for performing data analysis for plant phenotyping of single plants in a field and a data acquisition and evaluation system for performing data analysis for plant phenotyping of single plants in a field. Further, the invention relates to a mobile platform for use in the data acquisition and evaluation system. The method comprises the steps of capturing spectral data via a hyperspectral imaging sensor, capturing image data via an image sensor, capturing georeference data via an inertial measurement unit, spatializing the image data to generate georeferenced image data and a digital surface model, spatializing the spectral data, generating georeferenced spectral data based on the spatialized spectral data and the digital surface model and overlaying the georeferenced image data and georeferenced spectral data with field plan information to generate a high-resolution analysis data set.

Abstract: Techniques are provided for analyzing circular DNA in a biological sample (e.g., including cell-free DNA, such as plasma). For example, to measure circular DNA, cleaving can be performed to linearize the circular DNA so that they may be sequenced. Example cleaving techniques include restriction enzymes and transposases. Then, one or more criteria can be used to identify linearized DNA molecules, e.g., so as to differentiate from linear DNA molecules. An example criterion is mapping a pair of reversed end sequences to a reference genome. Another example criterion is identification of a cutting tag, e.g., associated with a restriction enzyme or an adapter sequence added by a transposase. Once circular DNA molecules (e.g., eccDNA and circular mitochondrial DNA) are identified, they may be analyzed (e.g., to determine a count, size profile, and/or methylation) to measure a property of the biological sample, including genetic properties and level of a disease.

Abstract: A chemical product formulation system automatically generates seed formulae from historic experiments data for the synthesis of a chemical product. Independent and dependent features are identified from the historic experiments data and feature importance scores are calculated using a supervised machine learning (ML) model. The feature importance scores are used to build data structures from which analytical rules are extracted. The analytical rules are further processed to derive the seed formulae which are user-editable. The intermediate formulae generated via user edits of the seed formulae are further validated and approved in order to be used as the final formulae which are employed for the synthesis of the chemical product.

Abstract: A method is disclosed for calculating and recalculating protein confidence values by recalculating peptide confidence values in proteomic analysis. A plurality of scans are performed of a sample that is proteolytically digested into surrogate peptide analytes. A plurality of spectra are obtained, and a plurality of peptides are identified. A protein database is searched for proteins matching peptides from the plurality of peptides. Peptide confidence values are determined for the set of peptides. A protein confidence value is calculated for each protein in the set of proteins. A protein from the set of proteins with a largest protein confidence value is selected, the largest protein confidence value for the protein is saved, the protein from the set of proteins is removed, and peptides corresponding to the protein is removed from the set of peptides. The protein confidence value is recalculated for each protein in the set of proteins.